Moderna appoints Juan Andres as chief operating officer and expands its vaccine portfolio
Moderna announced the appointment of Juan Andres as chief operating officer, effective Oct. 5, 2026, with a base salary of $800,000, a cash bonus target of up to 90% of salary and a new equity grant worth $5,000,000. At the same time, the company said Jerh Collins, chief technical operations and quality officer, will retire, and that its infectious disease franchise now includes five approved vaccines, adding a seasonal flu shot approved by the U.S. FDA and a flu‑COVID combination vaccine cleared by the European Commission.
Key points
- Moderna said Juan Andres will become chief operating officer on Oct.
- Moderna said the new chief operating officer role was created to support the company's expanding scale and diversification, and that the portfolio expansion reflects recent regulator approvals that enable new vaccine offerings.
- Juan Andres’s appointment and compensation do not guarantee higher financial results.
What happened
Moderna said Juan Andres will become chief operating officer on Oct. 5, 2026. Under his agreement he will receive a $800,000 annual base salary, a cash bonus with a target of 90% of salary and a $5,000,000 equity grant that vests over four years.
The company also disclosed that Jerh Collins, chief technical operations and quality officer, will retire, and that the infectious disease franchise has grown to five approved vaccines after the FDA approved Moderna’s seasonal flu vaccine and the European Commission authorized its seasonal flu‑plus‑COVID combination vaccine.
Compensation terms for the new chief operating officer
Company explanation
Moderna said the new chief operating officer role was created to support the company's expanding scale and diversification, and that the portfolio expansion reflects recent regulator approvals that enable new vaccine offerings.
What this does not mean
Juan Andres’s appointment and compensation do not guarantee higher financial results. Jerh Collins’s retirement does not necessarily cause production disruptions, though it will be monitored. The broader vaccine portfolio creates revenue potential only if demand remains stable and is not proof of immediate profit.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Moderna
A notification in your browser or on your phone when we publish about Moderna. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
